Lawmakers chide HHS for ‘eroding the pathway’ to Alzheimer’s treatments
By
Kimberly Bonvissuto
Mar 24, 2023
With personal stories of the effects that Alzheimer’s disease has had on them, lawmakers in a Senate Finance Committee hearing on Wednesday called for the federal government to speed up access to treatments....
Advocates ‘appalled’ as CMS again says it will not cover monoclonal antibody treatments for Alzheimer’s
By
Kimberly Bonvissuto
Feb 24, 2023
Advocates of those living with Alzheimer’s disease are expressing disappointment that the Centers for Medicare & Medicaid Services on Wednesday rejected a request to expand its coverage of monoclonal...
Focus on briefs: Dementia
Feb 01, 2023
Alzheimer’s blood test, Aducanumab approval issues, Medicare coverage of brain scans that diagnose dementia, Some at higher risk for Alzheimer’s
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
More news for Friday, Dec. 2
By
Kimberly Bonvissuto
Dec 02, 2022
Bill targets reform of CMS drug coverage authority in wake of aducanumab decision … FCC moves to improve affordable connectivity program for HUD residents … Partnership launches cybersecurity hub,...
Memory care breakthrough, or yet another false alarm?
By
John O'Connor
Dec 01, 2022
This week’s Alzheimer’s revelation is a hopeful sign, but even under the best possible scenario, much work remains.
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.
A stumbling block on the way to an Alzheimer’s cure
By
Lois A. Bowers
Nov 14, 2022
In a new study, 56% of participants said they were not likely to take part in a trial of a dementia-prevention drug. Senior living may be able to play a role in decreasing that percentage.